7/26/2021 8:55:23 AM
INmune Bio Announces Design Of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial And New Phase 1b AD Biomarker Data
7/22/2021 1:50:32 PM
INmune Bio Acquires LUMICKS' Z-Movi Cell Avidity Analyzer
7/12/2021 8:10:36 AM
INmune Bio Announces First Patient Treated With NK Cell Priming INKmune In High-Risk MDS
1/21/2021 7:12:18 AM
INmune Bio: XPro1595 To Decrease Neurodegeneration Biomarkers In Alzheimer’s Disease In Phase 1b Trial
10/5/2020 9:15:25 AM
INmune Bio To Present Data From Phase Ib Study Of Neuroinflammation In Alzheimer's Disease
5/14/2020 9:07:31 AM
INmune Bio Q1 Loss/Shr $0.19 Vs Loss $0.20 Last Year
1/2/2020 9:10:51 AM
INmune Bio Announces Publication Of New Positive Data In Journal